Phase 4 N=15 Sedative-Anxiolytic Effects on Simulated Driving Performance
Psychomotor Impairment
Primary: Standard Deviation of Lane Position (SLDP) — 40.08; 37.28; 36.06; 37.61 distance (cm)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=15 Norepinephrine-targeted Therapy for Action Control in Parkinson Disease
Parkinson Disease
Primary: Number of Subjects Who Develop an Adverse Event During the 7-week Treatment Period That is Determined to be Likely Related to the Study Medications. — 8 Participants
Phase 4 N=66 Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus
Myocardial Infarction · Diabetes Mellitus · Peripheral Arterial Disease
Primary: Maximal Platelet Aggregation in DM — 65; 78 percentage of aggregation — p=>0.05
Phase 4 N=90 Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis
Deep Vein Thrombosis · Postthrombotic Syndrome
Primary: Number of Participants With Postthrombotic Syndrome as Determined by Villalta Score — 3; 22 Participants — p=<0.0001
Phase 4 N=274 Digital Auscultation Test - IPF Data Collection
Idiopathic Pulmonary Fibrosis
Primary: Main Study - The Percentage of Collected Auscultation Points — 100; 100 PercentageOfAuscultationPointsCollected
Phase 4 N=54 Liposomal Bupivacaine After Arthroscopic Rotator Cuff Repair
Rotator Cuff Tear
Primary: Numeric Rating Pain Score [NRS] at Time of Block Resolution — 5.4; 5.8 Score on a scale — p=0.66
Phase 4 N=17 Treatment of Post-Extraction Dehisced Socket - A Case Series Study
Tooth Loss
Primary: Bone Volumetric Reduction From Baseline to 20 Weeks Post-extraction — 73.26 mm3
Phase 4 N=75 Insulin Schemes for Type 2 Diabetes Control
Type 2 Diabetes Mellitus
Primary: Differences in the Mean Daily Blood Glucose Between a Basal-bolus Scheme and NPH Schemes of Insulin. — 129.6; 135; 155.4; 156.2 mg/dl
Phase 4 N=81 Intravenous Versus Oral Acetaminophen in Primary Total Hip Arthroplasty
Osteoarthritis · Acetaminophen · Arthroplasty, Hip Replacement
Primary: 24 Hour Opioid Consumption — 3.0; 3.4 morphine milliequivalent
Phase 4 N=91 Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Bacterial Infections · Acute Bacterial Skin and Skin Structure Infection
Primary: Number of Infection-related Total Admitted Hospital Days — 4.8; 3.2 Days — p=0.003
Phase 4 N=551 Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
Diphtheria · Hepatitis B · Acellular Pertussis
Primary: Number of Seroprotected Subjects Against Anti-diphtheria (Anti-D), Anti-tetanus (Anti-T), Anti-hepatitis B (Anti-HBs), Anti-poliovirus Type 1, Anti-poliovirus Type 2…
Phase 4 N=34 PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria
Diabetes Mellitus, Type 2
Primary: Change in Endogenous Glucose Production (EGP) — 2.03; 1.92; 1.55; 1.68 mg/kg.min
Phase 4 N=100 Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training
Age-related Cognitive Decline
Primary: Change in Total Fluid Cognitive Score — 6.14; 3.71; 106.06; 105.85 score on a scale
Phase 4 N=92 Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs
Urinary Tract Infections, Recurrent
Primary: Time to Subsequent Infection as Defined From Time of Treatment Initiation to Recurrence of UTI — 101; 119 days
Phase 4 N=193 Plegridy Satisfaction Study in Participants
Relapsing-Remitting Multiple Sclerosis (RRMS)
Primary: Change From Baseline in Convenience Satisfaction Score of Treatment Satisfaction Questionnaire to Medication (TSQM-9) at Week 12 — 38.5; 38.5 score on a scale — p=0.56